Current Report Filing (8-k)
December 01 2017 - 4:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): December 1, 2017
Calyxt, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-38161
|
27-1967997
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification Number)
|
600 County Road D West, Suite 8
New Brighton, MN 55112
(Address and zip code of principal executive
offices)
(651) 683-2807
(Registrant’s telephone number,
including area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Exchange Act (17
CFR 240.12b-2).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 1, 2017, Calyxt, Inc. (the “Company”)
and Feng Zhang, Ph.D., the Company’s Chief Operating Officer, announced that Dr. Zhang’s employment with the Company
has terminated, effective as of December 1, 2017, to allow Dr. Zhang to pursue a career in academics. Dan Voytas, Ph.D., the Company’s
Chief Scientific Officer, will manage the Company’s scientific operations.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, Calyxt, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 1, 2017
|
|
|
|
|
CALYXT, INC.
|
|
|
|
|
|
|
By:
|
/s/ Joseph B. Saluri
|
|
|
|
Name: Joseph B. Saluri
|
|
|
|
Title: General Counsel, Executive Vice President – Corporate Development
|
|
Calyxt (NASDAQ:CLXT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calyxt (NASDAQ:CLXT)
Historical Stock Chart
From Sep 2023 to Sep 2024